Table 2.
Demographic characteristics of the patients.
| Parameters | |
|---|---|
| Female/male, n | 190/175 |
| Age (mean ± SD) | 42.6 ± 16.7 |
|
| |
| Age (year), n (%) | |
| <30 | 97 (36.6) |
| 31–50 | 160 (43.8) |
| >50 | 108 (29.6) |
|
| |
| Body mass index, (kg/m2), n (%) | |
| Underweight (<18.5) | 49 (13.4) |
| Normal weight (18.5–24.9) | 132 (36.2) |
| Overweight (24.5–29.9) | 104 (28.5) |
| Obese (>30) | 80 (21.9) |
|
| |
| Smoking | |
| Never smoker, n (%) | 205 (56.2) |
| Former smoker, n (%) | 61 (16.7) |
| Current smoker, n (%) | 99 (27.1) |
|
| |
| Smoking amount (pack-year), n (%) | |
| 0 | 205 (56.2) |
| 1–10 | 60 (16.4) |
| 11–20 | 58 (15.9) |
| >20 | 42 (11.5) |
| TB pass, n (%) | 12 (3.3) |
|
| |
| Subgroup analysis of TB patients (n = 12), n (%) | |
| Lung TB | 5 (41.7) |
| Extrapulmonary TB | 4 (33.3) |
| Unknown | 3 (25.0) |
|
| |
| TBF result, n (%) | |
| Positive | 51 (14.0) |
| Negative | 286 (78.3) |
| Indeterminate | 28 (7.7) |
| TBF prompting unit, n (%) | 52 (14.2) |
| Neurology | 30 (8.2) |
| Gastroenterology | 232 (63.6) |
| Rheumatology | 9 (2.5) |
| Dermatology | 42 (11.5) |
| Other | 52 (14.2) |
|
| |
| Chronic disease, n (%) | |
| HT | 40 (11.0) |
| DM | 32 (8.8) |
| Coronary artery disease | 23 (6.3) |
| Rheumatologic disease | 174 (47.7) |
| Obstructive lung diseases | 54 (14.8) |
| MS | 17 (4.7) |
| Malignancy | 15 (4.1) |
| Hypothyroidism | 16 (4.4) |
| Cardiac arrhythmia | 7 (1.9) |
| IBD | 35 (9.6) |
| CRF | 11 (3.0) |
|
| |
| Drugs used, n (%) | |
| Biological treatments | 169 (46.3) |
| Corticosteroid | 130 (35.6) |
|
| |
| COVID-19 status, n (%) | |
| Passed (PCR positive) | 46 (11.5) |
|
| |
| Severity of patients with COVID-19, n (%) | |
| Outpatient treatment | 32 (69.6) |
| Treatment in the hospital | 14 (30.4) |
|
| |
| Total length of hospital stay, n (%) | |
| 1–5 days | 5 (35.7) |
| 6–10 days | 6 (42.9) |
| >10 days | 3 (21.4) |
|
| |
| Treatment of 46 patients with COVID-19, n (%) | |
| Follow-up without treatment | 11 (23.9) |
| Favipiravir | 23 (50.0) |
| Plaquenil | 6 (13.0) |
| Favipiravir + plaquenil | 5 (10.9) |
| Anticoagulant | 9 (19.5) |
| Antibiotic | 2 (4.2) |
| Oxygen support | 1 (2.2) |
| Unknown | 1 (2.2) |
|
| |
| COVID-19 vaccine status, n (%) | |
| Not vaccinated | 315 (86.3) |
| Vaccinated | 50 (13.7) |
|
| |
| Reason for not being vaccinated, n (%) | |
| Due to the age limit for indication | 304 (96.5) |
| He/she refused to be vaccinated | 11 (3.5) |
TBF: Standard E TB-Feron ELISA (TBF) test; HT: hypertension; DM: diabetes mellitus; MS: multiple sclerosis; IBD: inflammatory bowel disease; CRF: chronic renal failure.